Ozempic Is About to Go Generic in India, China and Canada
#Ozempic #generic #patent expiration #India #China #Canada #Novo Nordisk #diabetes
📌 Key Takeaways
- Ozempic's patent is expiring soon in India, China, and Canada, allowing generic versions.
- This will likely make the diabetes and weight-loss drug more affordable in these markets.
- The move could increase access to treatment but may impact Novo Nordisk's sales.
- It reflects broader trends in pharmaceutical patent expirations and generic competition.
📖 Full Retelling
In India, China and several other nations, Novo Nordisk is on the verge of losing patent protection for its blockbuster weight loss drug, opening the door for cheaper competing versions.
🏷️ Themes
Pharmaceuticals, Market Access
Entity Intersection Graph
No entity connections available yet for this article.
Original Source
The generics are poised to shake up a global market for drugs that have transformed the treatment of obesity. Novo Nordisk and its competitor, Eli Lilly, have generated huge sales around the world, but access has been very limited. Generics promise to significantly increase the number of people taking the drugs, which have also been shown to help prevent heart attacks and strokes.
Read full article at source